Pacific Biosciences Appoints Kathy Ordoñez as Chief Commercial Officer
November 02 2017 - 4:11PM
Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced
today that Kathy Ordoñez has been named Chief Commercial Officer
and Executive Vice President.
Ms. Ordoñez brings more than thirty years of experience in the
life sciences and diagnostics industries, with senior roles at
Hoffmann-La Roche, Celera, Quest Diagnostics and RainDance
Technologies. At Roche, Kathy was responsible for the
formation of Roche Molecular Systems, where she served as President
and Chief Executive Officer for nine years and led the wide-scale
commercial application of the polymerization chain reaction (PCR)
technology to the research, diagnostic and forensic fields.
At Celera, she oversaw the establishment of the company’s
diagnostic sequencing business, which achieved a leadership
position in Sanger sequencing for clinical diagnostic
applications.
“I have worked with Kathy since the early days of PCR
commercialization, and I am pleased that she has agreed to bring
her substantial experience to our commercial endeavors,” said
Michael Hunkapiller, Pacific Biosciences Chairman and CEO.” I
am excited to continue to work with her to enhance our commercial
capability as we expand our research market presence and begin
development of our programs in the clinical market.”
As Chief Commercial Officer, Ms. Ordoñez will have senior
responsibility for the Company’s sales, support, and marketing
operations and remain a member of its Board of Directors. She
will report to Chairman and CEO Michael Hunkapiller.
Kathy holds a Bachelor’s degree in chemistry/physics and a
Doctorate of Science (Honorary) from Hartwick College in Oneonta,
NY.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de novo
genome assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences’ technology
provides high accuracy, ultra-long reads, uniform coverage, and is
the only DNA sequencing technology that provides the ability to
simultaneously detect epigenetic changes. PacBio® sequencing
systems, including consumables and software, provide a simple,
fast, end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to future availability, uses, quality or
performance of, or benefits of using, products or technologies, the
company’s commercial capability or market presence, the suitability
of the company’s products for particular applications or markets
and other future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences’ control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences’ most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.” Pacific
Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts
Investors:Trevin Rard650.521.8450ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024